Improving T cell movement into solid tumors
Engineered T cells for improved migration into solid tumor sites
['FUNDING_R21'] · UNIVERSITY OF COLORADO DENVER · NIH-11060864
This study is looking at ways to help special immune cells called T cells move better into solid tumors, which can be tough to treat, so that patients with hard-to-treat cancers might have more effective treatment options.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-11060864 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the ability of engineered T cells to migrate into solid tumors, which is a significant challenge in cancer treatment. The study aims to address the issue of T cells being excluded from tumor sites due to barriers like collagen-rich extracellular matrix. By developing T cells that can better penetrate these barriers, the research seeks to improve the effectiveness of immunotherapies, particularly in tumors that are currently resistant to treatment. Patients may benefit from this innovative approach if successful, as it could lead to more effective cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors that are currently difficult to treat with existing immunotherapies.
Not a fit: Patients with blood cancers or those whose tumors are already effectively treated by current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with solid tumors, improving their chances of recovery.
How similar studies have performed: While there have been advancements in T cell therapies, this specific approach to enhancing T cell migration into solid tumors is relatively novel and has not been extensively tested.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JACOBELLI, JORDAN — UNIVERSITY OF COLORADO DENVER
- Study coordinator: JACOBELLI, JORDAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy